Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase

MALVERN, Pa., Oct. 12 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced that the United States Patent and Trademark Office ("USPTO") issued U.S. Patent No. 7,811,560 claiming, among other things, purified collagenase, the active component in Auxilium's product XIAFLEX® (collagenase clostridium histolyticum).  The patent entitled "COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES" is expected to expire in July 2028.  The Company also announced that it has filed continuation applications with the USPTO, which, if granted, may expand the scope of patent claims covering XIAFLEX.

The patent's independent claims recite a drug product, a process for producing the drug product, and pharmaceutical formulations comprising the drug product.  The claimed drug product consists of isolated and purified clostridial collagenase I and II, with a mass ratio of about 1:1, and purity of at least 97% as measured by reverse phase high-performance liquid chromatography.  The process claims include processes for making the drug product.  The pharmaceutical formulation claims recite the drug product with appropriate excipient(s).  Dependent claims recite particular additional components of the drug product and pharmaceutical formulations, as well as additional process steps.

"We are very pleased that XIAFLEX now has patent protection which we expect will expire in July 2028," said Armando Anido, Chief Executive Officer and President of Auxilium Pharmaceuticals. "With one approved indication for XIAFLEX, a second in late-stage clinical trials, and many more potential indications in the pipeline, we believe that extending our patent protection for the next 18 years is an important accomplishment."

About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.  Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism.  Auxilium has four projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis).  Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development.  The Company is currently seeking a partner to further develop these product candidates.  Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system.  Auxilium also has options to all indications using XIAFLEX for non-topical formulations.  For additional information, visit

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the duration of any patent protection afforded the Company resulting from the Company's U.S. Patent No. 7,811,560 (the '560 patent); the expiration of the '560 patent; the potential expansion of the '560 patent claims resulting from any of the Company's continuing patent applications; the potential for XIAFLEX to be used in multiple indications; and products in development for Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease. All statements other than statements of historical facts contained in this release, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the words "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and similar expressions, as they relate to the Company, constitute forward-looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, the performance of third-party service providers, decisions by regulatory authorities regarding whether or when to proceed to the next phase of clinical trials, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 under the heading "Risk Factors," and in Auxilium's Quarterly Report on Form 10-Q for the period ended June 30, 2010, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at or by means of the Company's home page on the Internet at under the heading "For Investors -- SEC Filings." There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in forward-looking statements. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide the Company's expectations, plans or forecasts of future events and views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this release. Contacts:James E. Fickenscher/CFOAuxilium Pharmaceuticals, Inc.(484)  William Q. Sargent Jr./ VP IRAuxilium Pharmaceuticals, Inc.(484)  

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
2. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
3. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Star Scientific Comments on Roskamp Institutes Plans to Conduct Human Alzheimers Clinical Trials Using a Compound (RCP-006) Developed by Rock Creek Pharmaceuticals, Inc.
6. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
7. MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
8. Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
9. Access Pharmaceuticals, Inc. Signs $30M MuGard Supply Agreement With RHEI Pharmaceuticals HK LTD.
10. Meditrina Pharmaceuticals, Inc. Announces Allowance of Patent for Treatment of Endometriosis
11. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
Post Your Comments:
(Date:11/24/2015)... -- Teledyne DALSA , a Teledyne Technologies company and ... its CMOS X-Ray detector for mammography at the ... 3, at McCormick Place in Chicago . ... imaging will be on display in the South Hall, Booth ... X-Ray detectors is the industry benchmark for high speed imaging ...
(Date:11/24/2015)... 24, 2015 The uptake of recently approved and ... key driver of market growth to 2021, says GBI ... pipeline premium products for Type 1 Diabetes Mellitus (T1DM), will be a ... Research . --> The uptake of recently approved ... a key driver of market growth to 2021, says ...
(Date:11/24/2015)... NEWTOWN, Pa. , Nov. 24, 2015  NuShield, Inc., an industry leader in LCD screen ... mobile and stationary computer technology as part of their patient monitoring or electronic documentation system. ... ... ... ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests ... do not meet the device regulations. , Come up short in an inspection and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress and ... developer of renewable energy technologies capable of producing commercially useful amounts of thermal ... its WET™ and HHT™ Boiler System reactor core modules were presented to Congress ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to share their knowledge and experiences at a live taping of the next ... Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University Hotel ...
(Date:11/24/2015)... ... 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse ... of the staff members at their recovery center. The videos highlight some of the ... of the things that make their recovery program so unique. , “Making the decision ...
(Date:11/24/2015)... ... ... Shoulder , LLC launched their Pro Vest, the latest version of their widely popular weight ... under 10 hours. , The campaign, which will continue to run through ... market. , The PRO Vest provides consumers with a less expensive, one-size fits all comfort ...
Breaking Medicine News(10 mins):